We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us

Download Mobile App




Category-Defining Balloon Distal Access Catheter Allows Surgeons to Get Much Closer to Blood Clots

By HospiMedica International staff writers
Posted on 08 Feb 2023
Print article
Image: The Vena BDAC provides a superior solution to distal navigation (Photo courtesy of Vena Medical)
Image: The Vena BDAC provides a superior solution to distal navigation (Photo courtesy of Vena Medical)

Thrombectomy is a minimally invasive procedure for removing a blood clot and has now become standard of care treatment for patients with an acute ischemic stroke (AIS) secondary to a Large Vessel Occlusion (LVO). Surgeons use several available techniques, all of which aim to restore blood flow at the earliest. Now, a new device combines the balloon guide catheters and distal access catheters currently used in thrombectomy to remove clots from the brains of stroke victims, allowing clinicians to get the balloon much closer to the clot.

Vena Medical’s (Kitchener, ON, Canada) Vena Balloon Distal Access Catheter (BDAC) is a category-defining device that combines both a distal access catheter and balloon guide catheter to bring the balloon closer to the clot and stop residual clots in their tracks. Studies have shown that getting the balloon much closer to the clot improves key metrics such as First Pass Success Rate, enabling the removal of the clot in the first attempt and resulting in significantly better patient outcomes. Vena BDAC allows the use of manual aspiration to increase first pass effect, remove residual clots and reduce costs. It also reduces the number of devices to treat each patient and consequently, the cost of the procedure. The first five patients in the world have now been successfully treated using the Vena BDAC at Canadian hospitals.

“We’re proud to have the first patients to benefit from our Canadian developed technology within driving distance of our office, in the hands of world-class physicians. This is cutting-edge technology that would normally need to be launched somewhere far from here, but we’re excited to make an impact locally before we make an impact globally” said Michael Phillips, the CEO of Vena Medical.

Related Links:
Vena Medical 

Gold Member
Real-Time Diagnostics Onscreen Viewer
GEMweb Live
Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
Silver Member
Compact 14-Day Uninterrupted Holter ECG
NR-314P
New
Hysteroscopic Fluid Management System
HysteroFlow/HysteroBalance II

Print article

Channels

Critical Care

view channel
Image: The permeable wearable electronics developed for long-term biosignal monitoring (Photo courtesy of CityUHK)

Super Permeable Wearable Electronics Enable Long-Term Biosignal Monitoring

Wearable electronics have become integral to enhancing health and fitness by offering continuous tracking of physiological signals over extended periods. This monitoring is crucial for understanding an... Read more

Patient Care

view channel
Image: The newly-launched solution can transform operating room scheduling and boost utilization rates (Photo courtesy of Fujitsu)

Surgical Capacity Optimization Solution Helps Hospitals Boost OR Utilization

An innovative solution has the capability to transform surgical capacity utilization by targeting the root cause of surgical block time inefficiencies. Fujitsu Limited’s (Tokyo, Japan) Surgical Capacity... Read more

Health IT

view channel
Image: First ever institution-specific model provides significant performance advantage over current population-derived models (Photo courtesy of Mount Sinai)

Machine Learning Model Improves Mortality Risk Prediction for Cardiac Surgery Patients

Machine learning algorithms have been deployed to create predictive models in various medical fields, with some demonstrating improved outcomes compared to their standard-of-care counterparts.... Read more

Point of Care

view channel
Image: The PATHFAST hs-cTnI-II high-sensitivity troponin assay has been developed for the PATHFAST Biomarker Analyzer (Photo courtesy of Polymedco)

POC Myocardial Infarction Test Delivers Results in 17 Minutes

Chest pain is the second leading cause of emergency department (ED) visits by adults in the United States, generating over 7 million visits annually. In the event of a suspected heart attack, physicians... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.